Andrew Knudten
Chief Tech/Sci/R&D Officer chez Cirius Therapeutics, Inc.
Profil
M. Andrew Knudten est directeur de l'exploitation chez Jaguar Gene Therapy LLC et directeur technique chez Cirius Therapeutics, Inc. Auparavant, M. Knudten a occupé les postes de directeur technique et de vice-président des opérations techniques chez AveXis, Inc, de vice-président des opérations et de directeur d'usine chez Hospira, Inc, de responsable mondial de la fabrication sous contrat chez Novartis AG, de vice-président de la fabrication chez CoDa Therapeutics, Inc, et de directeur des opérations chez Amgen, Inc. Il a obtenu son diplôme de premier cycle à l'Université Concordia, un diplôme d'études supérieures à l'Université du Nebraska et un MBA à l'UCLA Anderson School of Management.
Postes actifs de Andrew Knudten
Sociétés | Poste | Début |
---|---|---|
Cirius Therapeutics, Inc.
Cirius Therapeutics, Inc. BiotechnologyHealth Technology Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 03/06/2019 |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | Chief Operating Officer | 01/02/2020 |
Anciens postes connus de Andrew Knudten
Sociétés | Poste | Fin |
---|---|---|
HOSPIRA, INC. | Corporate Officer/Principal | 01/09/2015 |
NOVARTIS AG | Corporate Officer/Principal | 01/03/2012 |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/02/2009 |
AMGEN INC. | Chief Operating Officer | 01/01/2007 |
AVEXIS INC | Chief Tech/Sci/R&D Officer | - |
Formation de Andrew Knudten
University of Nebraska | Graduate Degree |
Concordia University | Undergraduate Degree |
UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
AMGEN INC. | Health Technology |
NOVARTIS AG | Health Technology |
Entreprise privées | 5 |
---|---|
Hospira, Inc.
Hospira, Inc. Pharmaceuticals: MajorHealth Technology Hospira, Inc. provides injectable drugs and infusion technologies. It offers drugs, IV sets and clinical integration, infusion pumps, clinical software and implementation services. The company was founded on September 16, 2003 and is headquartered in Lake Forest, IL. | Health Technology |
OcuNexus Therapeutics, Inc.
OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Health Technology |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Cirius Therapeutics, Inc.
Cirius Therapeutics, Inc. BiotechnologyHealth Technology Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA. | Health Technology |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | Health Services |